Clinical Trials
27 trialsNCT07428486 2026-05-07
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT07498465 2026-05-05
A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia
Children's Oncology Group
Phase 1 Withdrawn
NCT05170828 2026-02-24
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
Phase 1 Withdrawn
NCT05521087 2025-06-22
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
Janssen Research & Development, LLC
Phase 1 Withdrawn
NCT03939585 2024-12-05
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
Case Comprehensive Cancer Center
Phase 1 Withdrawn
NCT05487495 2024-11-14
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma
Beijing Boren Hospital
Phase 1 Withdrawn
NCT05321940 2023-12-04
Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
University of Miami
Phase 1 Withdrawn
NCT05037669 2023-06-22
Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma
University of Pennsylvania
Phase 1 Withdrawn
NCT05168748 2022-12-21
CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia
Novartis
Phase 1 Withdrawn
NCT03768310 2022-07-21
CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)
Baylor College of Medicine
Phase 1 Withdrawn
NCT04464889 2021-10-08
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Medigene AG
Phase 1 Withdrawn
NCT02487459 2020-10-05
Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies
Bellicum Pharmaceuticals
Phase 1 Withdrawn
NCT03888534 2020-09-28
Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)
Takeda
Phase 1 Withdrawn
NCT03807063 2020-08-14
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 1 Withdrawn
NCT00004114 2020-07-31
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT02274506 2020-01-22
Infusion of Allogeneic, 3rd Party CD19-specific T Cells
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT02578511 2018-02-15
Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)
Medical College of Wisconsin
Phase 1 Withdrawn
NCT02815059 2018-01-31
Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone
University of Utah
Phase 1 Withdrawn
NCT02647190 2017-06-02
Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older
Memorial Sloan Kettering Cancer Center
Phase 1 Withdrawn
NCT02861040 2016-12-15
Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Northwestern University
Phase 1 Withdrawn
NCT00002956 2016-03-21
Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants
University of Alabama at Birmingham
Phase 1 Withdrawn
NCT00024115 2015-04-28
BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT00458744 2014-08-08
Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment
Children's Oncology Group
Phase 1 Withdrawn
NCT00521261 2014-03-05
Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Barbara Ann Karmanos Cancer Institute
Phase 1 Withdrawn
NCT00957320 2013-12-03
Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)
Emory University
Phase 1 Withdrawn
NCT00003435 2013-03-07
Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer
Duke University
Phase 1 Withdrawn
NCT00886496 2012-06-20
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia
Enzon Pharmaceuticals, Inc.
Phase 1 Withdrawn